

NHS Rotherham Clinical Commissioning Group

Operational Executive –26 June 2020

Strategic Clinical Executive – 1 July 2020

Primary Care Sub Group – 26 August 2020

Primary Care Committee – 9 September 2020

NHS Rotherham CCG prescribing incentive scheme payments 2019/20

Lead Executive:	Wendy Allott, Chief Finance Officer
Lead Officer:	Stuart Lakin, Head of Medicine Management
Lead GP:	Dr Sophie Holden, SCE GP Lead for Medicines Management

Purpose:

To inform Primary Care Committee the recommended practice payments awarded for the performance in the 2019/20:

1. Financial Incentive scheme (FIS)
2. Quality Incentive Scheme (QIS)

Background:

NHS Rotherham CCG operates two prescribing incentive schemes. Details of the payment structures are given below and the two 2019/20 schemes are enclosed

FIS -

If prescribing budget is underspent

40p/patient if 0 - 2.49% underspent

60p/patient if 2.5 – 4.99% underspent

80p/patient if $\geq 5\%$ underspent

If overspent

Practices can receive up to 10p / patient if they achieve 2 of the criteria.

Practices can receive up to 20p / patient if they achieve 3 of the criteria.

Practices can receive up to 30p / patient if they achieve 4 of the criteria

Practices can receive up to 40p / patient if they achieve 5 of the criteria

QIS

Practices can receive up to 10p / patient if they achieve 2 of the criteria.

Practices can receive up to 20p / patient if they achieve 4 of the criteria.

Practices can receive up to 30p / patient if they achieve 6 of the criteria

Practices can receive up to 40p / patient if they achieve 8 of the criteria

Practices can receive up to 50p / patient if they achieve 10 of the criteria

Primary Care Delegation Responsibility:

Does this paper relate to Rotherham CCG or delegated business?

Rotherham CCG	✓
Delegated	
Both Rotherham CCG and delegated	

Please indicate which area of delegated responsibility this paper covers:

Commissioning, procurement and management of GMS,PMS and APMS contracts including taking contractual action	
Newly designed enhanced services (including DES)	
Local incentive schemes	
Discretionary payments	
Commissioning urgent care for out of area registered patients	
Planning Primary medical care services (PMCS)	
Managing practices with CQC / quality concerns	
Decisions on premise cost directions	
Planning the commissioning of PMCS	
Manage the delegated allocation for commissioning of PMCS	
Assurance to the governing body on the quality and safety of PMCS	

Please indicate which of the Delegated Duties Decisions this paper requires:-

<ul style="list-style-type: none"> Delegated Duties – iii – Decisions in relation to the establishment of new GP practices (including branch surgeries) and closures of GP practices. 	N/A
<ul style="list-style-type: none"> Delegated Duties – iv – Decisions about ‘discretionary payments’. 	N/A
<ul style="list-style-type: none"> Delegated Duties – v – Decisions about commissioning urgent care (including home visits as required) for out of area registered patients. 	N/A
<ul style="list-style-type: none"> Delegated Duties – b – The approval of practice mergers. 	N/A

Analysis of key issues and of risks

The total amount available under both schemes is £344,537. The recommended total payment for 2019/20 = £207,000 = 60.1% of the available amount.

	Amount available	Amount paid	% total
QIS	£132,514	£96,755	73%
FIS	£212,023	£110,337	52%
Total	£344,537	£207,092	60.1%

A total of 94 audits were received and reviewed by the Medicines Management

Committee

62 Audits were required by the 2019/20 QIS

36 Audits were appeals against the outcome 22 of these appeals were approved.

A detailed breakdown of practice performance is attached.

It should be noted that the financial structure of the prescribing incentive schemes up to £1.30/patient has not been reviewed for several years.

Patient, Public and Stakeholder Involvement:

Both incentive schemes are designed to improve the quality and cost effective of prescribing. The specific criteria are often developed with reference to national guidance or a recognised evidence base.

Equality Impact:

None

Financial Implications:

CCG investment for 2019/20 = £207,092 this money has been accrued for from 2019/20 budgets.

Human Resource Implications:

None.

Procurement Advice:

None

Data Protection Impact Assessment:

None

Approval history:

Medicines Management Committee - 17 June 2020

Operational Executive - 26 June 2020

Recommendations:

The paper is for noting.

Paper is for noting